Valuation: Vericel Corporation

Market Cap 2.03B 1.77B 1.66B 1.52B 2.85B 194B 2.85B 19.96B 7.7B 98.87B 7.61B 7.44B 319B P/E 2026 *
71.6x
P/E 2027 * 44.9x
Enterprise Value 2.03B 1.77B 1.66B 1.52B 2.85B 194B 2.85B 19.96B 7.7B 98.87B 7.61B 7.44B 319B EV / Sales 2026 *
6.02x
EV / Sales 2027 * 5.15x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -
1 day+1.69%
1 week+1.26%
Current month+0.80%
1 month-4.92%
3 months-0.62%
6 months+23.94%
Current year+11.69%
1 week 39.05
Extreme 39.05
40.87
1 month 37.35
Extreme 37.35
43.34
Current year 28.95
Extreme 28.95
49.32
1 year 28.95
Extreme 28.95
49.32
3 years 28.95
Extreme 28.95
63
5 years 17.3
Extreme 17.3
63
10 years 2
Extreme 2
68.94
Manager TitleAgeSince
Chief Executive Officer 62 01/03/2013
Director of Finance/CFO 51 25/01/2021
Chief Tech/Sci/R&D Officer - 01/01/2024
Director TitleAgeSince
Director/Board Member 71 28/09/2005
Chairman 75 05/10/2012
Director/Board Member 57 23/08/2013
Date Insider Type Main position Quantity % Market Cap. Importance
12/08/26 Exercice

Director

21,000 0.0411%
03/08/26 Exercice

Chief Operating Officer

30,000 0.0587%
30/07/26 Exercice

Controller/Auditor

13,500 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
+1.69%+1.26%+26.44%+18.29% 2.03B
+0.72%+3.85%+34.96%-2.54% 79.7B
+5.56%+26.98%+587.35%+82.58% 69.04B
+1.36%+5.33%-8.90%-29.50% 60.82B
-0.78%-2.04%-11.65%+27.42% 47.16B
+0.66%+1.43%+5.02%+156.67% 46.38B
+2.87%+4.25%+60.22%-12.54% 32.37B
+1.83%+4.26%+49.81%+118.47% 25.27B
+0.68%+6.45%+12.00%+172.03% 22.72B
+1.04%0.00%+59.62%+105.60% 15.7B
Average +1.54%+2.92%+81.49%+63.65% 40.12B
Weighted average by Cap. +1.68%+4.20%+117.03%+50.99%

Financials

2026 *2027 *
Net sales 336M 294M 276M 252M 473M 32.14B 473M 3.31B 1.28B 16.41B 1.26B 1.23B 52.92B 393M 343M 323M 294M 553M 37.56B 553M 3.87B 1.49B 19.18B 1.48B 1.44B 61.84B
Net income 29.29M 25.6M 24.06M 21.95M 41.2M 2.8B 41.21M 289M 111M 1.43B 110M 108M 4.61B 47.29M 41.33M 38.84M 35.44M 66.52M 4.52B 66.54M 466M 180M 2.31B 178M 174M 7.44B
Net Debt - -
Logo Vericel Corporation
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Employees
398
Date Price Change Volume
23/09/26 $40.22 +1.69% 546,953
21/09/26 $39.55 -1.17% 402,175
18/09/26 $40.02 -0.02% 1,126,476
17/09/26 $40.03 -0.45% 536,421
16/09/26 $40.21 +1.23% 490,484
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
40.22USD
Average target price
60.57USD
Spread / Average Target
+50.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VCEL Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!